Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the developmental plasticity between teeth and taste buds in cichlid fishes and reports no new experimental findings, highlighting potential implications for craniofacial organ patterning and regeneration.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study analyzed research trends in discoid lupus erythematosus, revealing shifting focus areas and highlighted the importance of interdisciplinary collaboration between dermatology and other fields.

A new method was developed to detect pesticide residues on apples without damage.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

This study found that oral spironolactone is generally well tolerated and may be effective for treating female-pattern hair loss, with improvements in hair regrowth stability as measured by Sinclair scores.

The document concludes that stem cells and their environments are crucial for skin and hair health and have potential for medical treatments.

This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This article discusses the off-label use of low-dose oral minoxidil for alopecia and reports no new clinical findings, noting its presumed mechanism is enhancing hair follicle microcirculation with minimal blood pressure effects.

This review discusses the various off-label treatments for alopecia areata, highlighting that these therapies may promote hair growth but are not curative.

In this open-label study, the researchers observed that using Kerascalp hair serum daily for 90 days improved hair thickness, density, and strength while reducing hair loss in subjects with mild to moderate androgenetic alopecia, with benefits persisting even after discontinuation.

The study found that Asthimajjapachak Churna led to greater improvement in managing hair fall among young females compared to Shwadamshtradi Rasayana Churna, particularly through alleviation of Asthigata dosha.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

This open-label study suggests that combining valproate, lamotrigine, and a benzodiazepine can significantly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies.

This review identifies several off-label uses of H-1 antihistamines in dermatology beyond itch and urticaria control, though the evidence is weak and further trials are needed.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This paper reviews the current evidence regarding the off-label use of spironolactone for acne management, noting that despite its long-standing application in acne treatment, it has not yet received FDA approval for this indication.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

This study found that Hopx labels a long-lived progenitor population in hair follicles, which contributes to hair follicle stem cell homeostasis and has an alternative origin from previously thought progenitors.

This review discusses the integration of drug repurposing with personalized medicine through off-label prescribing and reports no new results, highlighting the potential for systematic exploration using omics technologies.

This review reported that spironolactone, used off-label, is an effective and safe treatment option for adult women with acne, presenting fewer adverse reactions compared to common treatments like antimicrobials, which carry the risk of microbial resistance.

This review highlights emerging evidence that low-dose oral minoxidil could be used off-label to treat androgenetic alopecia, offering insights into its potential mechanisms and clinical applications beyond its current role in treating hypertension.

This study found that 42% of red yeast rice dietary supplements did not list monacolin concentrations on their labels, and only half of those that did contained the declared amounts.

This study examined the cardiovascular safety of oral minoxidil, used off-label for androgenetic alopecia, particularly as its usage expands in real-world settings, although specific results were not detailed in the abstract.